Patients with chronic kidney disease (CKD) are often prescribed antidepressants, including selective serotonin reuptake inhibitors (SSRIs), for management of depression. The SSRIs have a very favorable safety profile overall but have been associated with bleeding risk as a result of their blocking serotonin uptake in platelets and the resultant inhibition of platelet aggregation.